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Abstract
Aims/hypothesis Microvascular complications in the heart and
kidney are strongly associated with an overall rise in inflamma-
tion. AnnexinA1 (ANXA1) is an endogenous anti-inflammatory
molecule that limits and resolves inflammation. In this study, we
have used a bedside to bench approach to investigate: (1)
ANXA1 levels in individuals with type 1 diabetes; (2) the role
of endogenous ANXA1 in nephropathy and cardiomyopathy in
experimental type 1 diabetes; and (3) whether treatment with
human recombinant ANXA1 attenuates nephropathy and cardio-
myopathy in a murine model of type 1 diabetes.
Methods ANXA1 was measured in plasma from individuals
with type 1 diabetes with or without nephropathy and healthy
donors. Experimental type 1 diabetes was induced in mice by
injection of streptozotocin (STZ; 45 mg/kg i.v. per day for 5
consecutive days) in C57BL/6 or Anxa1−/− mice. Diabetic
mice were treated with human recombinant (hr)ANXA1
(1 μg, 100 μl, 50 mmol/l HEPES; 140 mmol/l NaCl; pH 7.4,
i.p.) or vehicle (100 μl, 50 mmol/l HEPES; 140 mmol/l NaCl;
pH 7.4, i.p.).
Results Plasma levels of ANXA1 were elevated in individuals
with type 1 diabetes with/without nephropathy compared with
healthy individuals (66.0±4.2/64.0±4ng/mlvs35.9±2.3ng/ml;
p< 0.05). Comparedwith diabetic wild-type (WT)mice, diabetic
Anxa1−/− mice exhibited a worse diabetic phenotype and devel-
oped more severe cardiac (ejection fraction; 76.1 ± 1.6% vs
49.9 ± 0.9%) and renal dysfunction (proteinuria; 89.3 ± 5.0 μg/
mg vs 113.3 ± 5.5 μg/mg). Mechanistically, compared with non-
diabeticWTmice, the degree of the phosphorylation of mitogen-
activated protein kinases (MAPKs) p38, c-Jun N-terminal kinase
(JNK) and extracellular signal-regulated kinase (ERK) was sig-
nificantly higher in non-diabetic Anxa1−/−mice in both the heart
and kidney, and was further enhanced after STZ-induced type 1
diabetes. Prophylactic treatment with hrANXA1 (weeks 1–13)
attenuated both cardiac (ejection fraction; 54.0 ± 1.6% vs
72.4 ± 1.0%) and renal (proteinuria; 89.3 ± 5.0 μg/mg vs
53.1 ± 3.4 μg/mg) dysfunction associated with STZ-induced
diabetes, while therapeutic administration of hrANXA1 (weeks
8–13), after significant cardiac and renal dysfunction had already
developed, halted the further functional decline in cardiac and
renal function seen in diabetic mice administered vehicle. In
addition, administration of hrANXA1 attenuated the increase in
phosphorylation of p38, JNK and ERK, and restored phosphor-
ylation of Akt in diabetic mice.
Conclusions/interpretation Overall, these results demonstrate
that ANXA1 plasma levels are elevated in individuals with
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type 1 diabetes independent of a significant impairment in
renal function. Furthermore, in mouse models with STZ-
induced type 1 diabetes, ANXA1 protects against cardiac
and renal dysfunction by returning MAPK signalling to base-
line and activating pro-survival pathways (Akt). We propose
ANXA1 to be a potential therapeutic option for the control of
comorbidities in type 1 diabetes.
Keywords Akt . Annexin A1 . Diabetes . Diabetic
cardiomyopathy . Diabetic nephropathy .MAPK .
Microvascular complications . Type 1 diabetes
Abbreviations
ACR Albumin-to-creatinine ratio
ANXA1 Annexin A1
CRP C-reactive protein
EF Ejection fraction
ERK Extracellular signal-regulated kinase
FAC Fractional area change
FPR2 Formyl peptide receptor 2
FS Fractional shortening
Hr Human recombinant
JNK c-Jun N-terminal kinase
MAPK Mitogen-activated protein kinase
PCT Proximal convoluted tubules
PI3K Phosphoinositide-3 kinase
STZ Streptozotocin
WT Wild-type
Introduction
Type 1 diabetes is an autoimmune disease often diagnosed in
childhood that is characterised by the loss of insulin producing
beta cells, which leads to hyperglycaemia [1]. Even with strict
glycaemic control using rigorous insulin management, micro-
vascular complications including diabetic nephropathy [2]
and diabetic cardiomyopathy [3] develop over time. The mi-
crovascular complications associated with diabetes are key
drivers of morbidity (and ultimately mortality) rates, and
therefore put a significant economic burden on healthcare pro-
viders. Most notably, there are no specific therapeutic inter-
ventions that prevent, delay or reduce the microvascular com-
plications associated with diabetes. Diabetic nephropathy is
the primary cause of death in 21% of people with type 1
diabetes [4], and cardiovascular disease, which includes dia-
betic cardiomyopathy, accounts for 44% of all fatalities in type
1 diabetes [5]. Both pathologies are characterised by an im-
pairment in function (kidney [proteinuria [6]], heart [impair-
ment in systolic contractility [7]]) caused by local
inflammation [8], endothelial dysfunction [9] and loss of sur-
vival pathways, the latter of which predisposes tissues to
injury.
Resolution of inflammation and modulation of survival
pathways are critical to normal physiology and are often altered
in disease states. Annexin A1 (ANXA1) is a 37 kDamember of
the multigene annexin family with anti-inflammatory and pro-
resolving activities [10]. The N-terminus of each family mem-
ber varies giving each its unique functionality [11]. ANXA1
binds formyl peptide receptor 2 (FPR2/ALX), downregulating
the production of proinflammatory processes but activating
pro-survival pathways via protein kinase C [12]. ANXA1 levels
are modulated in many disease states including cancer [13],
multiple sclerosis [14], cystic fibrosis [15] and obesity/the met-
abolic syndrome [16]. Human recombinant ANXA1
(hrANXA1) or its N-terminal peptide (Ac2-26) have therapeu-
tic benefits in many experimental models of disease, including
rheumatoid arthritis [17], atherosclerosis [18] and nonalcoholic
steatohepatitis [19].
The role of ANXA1 as a pro-resolving-like molecule in
type 1 diabetes is unknown. Therefore, this study was de-
signed to investigate: (1) the plasma levels of ANXA1 in
individuals with diabetes with/without nephropathy; (2) the
role of endogenous ANXA1 in an animal model of type 1
diabetes and in the subsequent development of microvascular
complications (diabetic cardiomyopathy and diabetic ne-
phropathy); (3) if prophylactic daily administration with
hrANXA1 prevents diabetic cardiomyopathy and/or nephrop-
athy; and (4) if therapeutic intervention with hrANXA1 (after
microvascular complications have developed) can halt the
progression of diabetic cardiomyopathy and/or nephropathy.
Methods
Use of human participants: ethics statement The study was
approved by the research ethics committee and was undertak-
en in adherence to the Declaration of Helsinki. All participants
gave written informed consent. Participants with type 1 dia-
betes were recruited from the diabetes outpatient clinic of
Guy’s and St Thomas Hospitals (London, UK). Healthy do-
nors were recruited from the William Harvey Research
Institute (London, UK) and both covered by ethical approval.
Non-fasting plasma was obtained from participants with type
1 diabetes with or without a diagnosis of diabetic nephropathy
and healthy donors.
Use of experimental animals: ethics statement The animal
protocols followed in this study were approved by the Animal
Welfare Ethics Review Board (AWERB) of Queen Mary
University of London in accordance with the derivatives of
both the Home Office guidance on the Operation of Animals
(Scientific Procedures Act 1986) published by Her Majesty’s
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Stationery Office and the Guide for the Care and Use of
Laboratory Animals of the National Research Council. This
study was performed under licence issued by the Home Office
(Procedure Project Licence; 70/8350) (see the electronic sup-
plementary material [ESM] Methods for further details).
Human study populationDetails on the study population are
provided in the ESM Methods and ESM Table 1. The popu-
lation included healthy volunteers (n = 20), participants with
type 1 diabetes (n = 20) and participants with type 1 diabetes
and nephropathy (n = 22). Plasma ANXA1 and C-reactive
protein (CRP) was measured using standard ELISA (de-
scribed below). Correlation studies were carried out between
plasma ANXA1, plasma CRP and BMI.
Animal model of diabetes Experimental diabetes was in-
duced in 10-week-old wild-type (WT) male C57BL/6 or
Anxa1−/− mice (Anxa1tmiRjf on a C57BL/6 background)
(Charles River Laboratories, Margate, UK). Diabetes was in-
duced using streptozotocin (STZ; 45 mg/kg i.p. in 0.9 mol/l
citrate buffer, 5 days, n = 8), while shammice received vehicle
only (10 ml/kg, 0.9 mol/l citrate buffer i.p., 5 days, n = 8).
hrANXA1 was produced and purified as previously published
[18]. Treatment groups received either prophylactic treatment
(weeks 1–13 after STZ administration, n = 6), treatment dur-
ing STZ administration (days 1–5, n = 6) or therapeutic treat-
ment (weeks 8–13 after STZ administration, n = 6) with
hrANXA1 (1 μg, 100 μl, 50 mmol/l HEPES; 140 mmol/l
NaCl; pH 7.4, i.p.) from weeks 1–13 or vehicle. The study
has been repeated in two independent experiments each time
animals were randomly assigned a treatment group and all
analysis of in vivo function was assessed in a blinded fashion.
OGTT Mice were fasted for 18 h prior to testing, given an
oral bolus of glucose (1 g/kg in H2O p.o.) and blood glucose
was measured at time 0 and then at 15 min intervals for
120 min by tail vein puncture.
Assessment of cardiac function in vivoCardiac functionwas
assessed in mice by echocardiography in vivo as previously
described [20]. Briefly, at either 7 or 13 weeks after STZ or
vehicle administration, anaesthesia was induced and two-
dimensional B-mode and M-mode echocardiography images
were recorded using a Vevo-770 imaging system
(VisualSonics, Toronto, ON, Canada).
Blood and biochemical analysisUrea, creatinine and sodium
were measured by a commercial veterinary testing laboratory
(IDEXX, Wetherby, UK); serum insulin and urine albumin
were measured using commercially available ELISA kits
(Abcam, Cambridge, UK and Bethyl Laboratories,
Montgomery, TX, USA).
ELISA for ANXA1 Concentrations of ANXA1 in human
plasma, mouse serum or protein lysates from heart and kidney
were measured by ELISA as previously reported [21–23] (see
ESM Methods for further details).
Histological analysis Kidneys were fixed in 10% neutral-
buffered formalin for 48 h before being dehydrated with
70% ethanol. Tissues were embedded in paraffin and 4 μm
sections were cut. Tissue was either stained with periodic ac-
id–Schiffs (PAS; Sigma, St Louis, MO, USA) or Sirius Red
(Abcam) as previously described [24] (see ESM Methods for
further details).
Western blot analysis The degree of phosphorylation of
Ser473 on Akt/p-Akt (Cell Signaling Technology, Danvers,
MA, USA), Thr180/Tyr182 on p38/p-p38 (New England
Biolabs, Ipswich, MA, USA), Thr183/Tyr185 on c-Jun N-ter-
minal kinase (JNK)/p-JNK (Abcam) and Thr202/Tyr204 on ex-
tracellular signal-regulated kinase (ERK1/2)/p-ERK1/2 (New
England Biolabs) was measured by semi-quantitative western
blot analyses in mouse heart and kidney tissue as described
previously [20, 25] (see ESM Methods for further details).
Statistical analysisAll data in the text and figures are present-
ed as mean and SEM of n observations, where n represents the
number of animals studied. All statistical analysis was calcu-
lated using GraphPad Prism 6 (GraphPad Software, San
Diego, CA, USA). Data without repeated measurements were
assessed by a one-way ANOVA followed by Bonferroni post
hoc test (multiple comparison) or unpaired Student’s t test
where appropriate. OGTTs were analysed using the area under
the receiver operating characteristic (ROC) curve. A p value of
<0.05 was considered to be statistically significant.
Results
Participants with type 1 diabetes have elevated ANXA1
plasma levels Figure 1a shows plasma concentration of
ANXA1 in healthy donors and in participants with diabetes
with/without nephropathy. The median age and sex distribu-
tion of the three test groups was similar (ESM Table 1). Plasma
levels of ANXA1were higher in individuals with diabetes with
or without a diagnosis of diabetic nephropathy compared with
healthy individuals (Fig. 1a), with no observed sex difference
in ANXA1 concentration (ESM Fig. 1). Participants with dia-
betic nephropathy have higher plasma levels of CRP (a marker
of systemic inflammation) compared with those with no ne-
phropathy (Fig. 1b). However, we found no significant positive
correlation between CRP and ANXA1 or BMI and ANXA1
(ESM Fig. 2a, b), but there was a strong positive correlation
between plasma CRP and BMI (ESM Fig. 2c).
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Diabetic Anxa1−/− mice have a more severe diabetic phe-
notype as a result of STZ-induced type 1 diabetes Using a
reverse translational approach, from humans to rodents, we
wanted to understand the biological effect of modulating
endogenous ANXA1 levels in a mouse model of type 1
diabetes in both WT and Anxa1−/− mice. When compared
with non-diabetic mice, diabetic mice demonstrated a sig-
nificant decrease in ANXA1 levels in both the heart and
kidney (Fig. 1c, d), while secreted ANXA1 levels in the
serum were unchanged (Table 1). Diabetic WT and
Anxa1−/− mice had depleted serum insulin levels, resulting
in elevated non-fasted blood glucose levels (Table 1).
Interestingly, diabetic Anxa1−/− mice had significantly in-
creased non-fasted blood glucose (Table 1) and a more se-
vere impairment of OGTT compared with diabetic WT
mice, suggesting Anxa1−/−mice have a more severe diabetic
phenotype (Fig. 1e, f).
DiabeticAnxa1−/−mice have more severe cardiac dysfunc-
tion as a result of STZ-induced type 1 diabetes Next, we
assessed the role of endogenous ANXA1 on cardiac dysfunc-
tion associated with STZ-induced diabetes using echocardiog-
raphy. When compared with non-diabetic WT mice, diabetic
WTmice demonstrated a significant reduction in ejection frac-
tion (EF) (Fig. 2a and ESM Fig. 3b), fractional shortening
(FS) (Fig. 2b and ESM Fig. 3b) and fractional area change
(FAC) (Fig. 2c). This indicates the development of systolic
cardiac dysfunction, with even further deterioration in EF,
FS and FAC observed in diabetic Anxa1−/− mice (Fig. 2a–c
and ESM Fig. 3d). Diabetic WT and Anxa1−/− mice both
Fig. 1 (a) ANXA1 levels were measured by sandwich ELISA in the
plasma of healthy donors (n = 20), participants with type 1 diabetes
(T1DM) without diabetic nephropathy (n = 20) and participants with type
1 diabetes with diabetic nephropathy (n = 22). (b) CRP was measured in
plasma of participants with type 1 diabetes with and without diabetic
nephropathy. (c, d) ANXA1 levels were measured by sandwich ELISA
in mice at week 13 after STZ-induced diabetes in serum in tissue lysates
from (c) the heart and (d) the kidney. (e) An OGTT was performed at
week 13. Experimental groups: WT + vehicle (100 μl, 0.1 mol/l citrate
buffer, i.p. for 5 days; white triangles), WT + STZ (45 mg/kg, 0.1 mol/l
citrate buffer, i.p. for 5 days; black triangles), Anxa1−/− + vehicle (100 μl,
0.1 mol/l citrate buffer, i.p. for 5 days; white circles) and Anxa1−/− + STZ
(45 mg/kg, 0.1 mol/l citrate buffer, i.p. for 5 days; black circles). (f) AUC
of the OGTT. Black bars, vehicle; white bars, STZ. Data analysed by a
Student’s t test (b–d) or by one-way ANOVA followed by a Bonferroni
post hoc test (a, f), and expressed as mean ± SEM. n = 6–8 per group.
*p < 0.05, **p < 0.01
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demonstrated a significant increase in intra-ventricular septum
thickness, suggesting the presence of severe concentric hyper-
trophy (Fig. 2d and ESM Fig. 3a–d).
Western blot analysis of tissue from the hearts of mice
demonstrated that, compared with non-diabetic WT mice, di-
abetic WT mice demonstrated a significant increase in the
degree of phosphorylation of Thr180/Tyr182 on p38, Thr183/
Tyr185 on JNK and Thr202/Tyr204 on ERK1/2 (Fig. 2e–g).
Interestingly, compared with non-diabetic WT mice, non-
diabetic Anxa1−/−mice demonstrated significantly more phos-
phorylation of Thr180/Tyr182 on p38, Thr183/Tyr185 on JNK
and Thr202/Tyr204 on ERK1/2, suggesting activation at basal
state, while diabetic Anxa1−/− mice demonstrated a further
increase in the degree of phosphorylation of Thr180/Tyr182
on p38, Thr183/Tyr185 on JNK and Thr202/Tyr204 on ERK1/2
(Fig. 2e–g).
Diabetic Anxa1−/− mice have more severe renal dysfunc-
tion as a result of STZ-induced type 1 diabetes To investi-
gate the role of endogenous ANXA1 on renal dysfunction
associated with STZ-induced diabetes, renal function was
assessed using urinary variables. When compared with non-
diabetic WT mice, diabetic WT mice demonstrated a
significant increase in urinary albumin-to-creatinine ratio
(ACR) (Fig. 3a) and fractional excretion of sodium
(Fig. 3b), indicating the presence of proteinuria and tubular
dysfunction, which was further exacerbated in diabetic
Anxa1−/− mice (Fig. 3a, b).
Histological analysis of renal tissue from non-diabetic
WT mice and Anxa1−/− mice demonstrated no morphologi-
cal alterations, including a well-preserved brush border in
the S1–S2 segment of the proximal convoluted tubules
(PCT) and normal glomerular structures at basal state
(Fig. 3e). However, kidneys from diabetic WT mice dem-
onstrated PCT dilation, a marked increase in the degree of
vascular degeneration and a loss of brush borders in the S1–
S2 segment of the PCT, demonstrating morphological fea-
tures consistent with renal dysfunction, specifically tubular
dysfunction (Fig. 3e). Kidneys from diabetic WT mice also
exhibited an increase in glomerular size (Fig. 3c, e), sug-
gesting glomerular hypertrophy consistent with observed
renal dysfunction and proteinuria. All histological markers
were further exacerbated in the kidneys from diabetic
Anxa1−/− mice (Fig. 3e), specifically the observed loss of
brush border in the S1–S2 segment of the PCT. DiabeticWT
mice also exhibited significant increase in Sirius Red
Fig. 2 Measurements of cardiac function in WT and Anxa1−/− mice: (a)
EF, (b) FS and (c) FAC at week 13, and (d) intra-ventricular septum
diameter (IVSd). (e–g) Densitometric analysis of bands is expressed as
relative to sham absorbance of (e) phosphorylated p38 (pThr180/Tyr182)
corrected to total p38 and normalised using the WT + vehicle band, (f)
phosphorylated JNK (pThr183/Tyr185) corrected to total JNK and normal-
ised using the WT + vehicle band, and (g) phosphorylated ERK1/2 (p-
Thr202/-Tyr204) corrected to total ERK1/2 and normalised using theWT +
vehicle band. Experimental groups: WT + vehicle (100 μl, 0.1 mol/l
citrate buffer, i.p. for 5 days), WT + STZ (45 mg/kg, 0.1 mol/l citrate
buffer, i.p. for 5 days),Anxa1−/− + vehicle (100μl, 0.1 mol/l citrate buffer,
i.p. for 5 days) and Anxa1−/− + STZ (45 mg/kg, 0.1 mol/l citrate buffer,
i.p. for 5 days). Black bars, vehicle; white bars, STZ. In (g) solid bars,
ERK1; hatched bars, ERK2. Data analysed by a one-way ANOVA
followed by a Bonferroni post hoc test and expressed as mean ± SEM.
n = 6–8 per group. *p < 0.05
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staining for collagen I and III in the interstitial spaces
(Fig. 3d, e), indicating the development of renal fibrosis,
while kidneys from diabetic Anxa1−/− mice had significant-
ly more Sirius Red staining specifically in the interstitial
spaces and around the vasculature (Fig. 3d, e).
Western blot analysis of the tissue from the kidneys
of diabetic WT mice demonstrated a significant increase
in the degree of phosphorylation of Thr180/Tyr182 on
p38, Thr183/Tyr185 on JNK and Thr202/Tyr204 on
ERK1/2 (Fig. 4). Interestingly, compared with non-
diabetic WT mice, non-diabetic Anxa1−/− mice demon-
strated significantly more phosphorylation of Thr180/
Tyr182 on p38 and Thr183/Tyr185 on JNK at basal state
(Fig. 4a, b), while diabetic Anxa1−/− mice demonstrated
a further increase in the degree of phosphorylation of
Thr180/Tyr182 on p38, Thr183/Tyr185 on JNK and Thr202/
Tyr204 on ERK1/2 (Fig. 4).
Prophylactic daily treatment with hrANXA1 protects
against cardiac and renal dysfunction caused by STZ-
induced model of type 1 diabetesWhen compared with un-
treated diabetic mice, diabetic mice treated with daily
hrANXA1 from weeks 1–13 or during days 1–5 exhibited
no change in serum insulin level, non-fasted blood glucose
or OGTT (Table 1), suggesting treatment with hrANXA1
did not alter the underlying diabetic phenotype. When left
ventricular function was assessed using echocardiography, di-
abetic mice had reduced EF, FS and FAC compared with non-
diabetic mice (Fig. 5a–c). Treatment with hrANXA1 from
weeks 1–13 significantly attenuated the decreases in EF, FS
Fig. 3 Measurements of renal
function in WT and Anxa1−/−
mice: (a) urine ACR, (b)
fractional excretion of sodium, (c)
glomerular area and (d)
quantification of Sirius Red
staining. (e) Representative
images of periodic acid–Schiffs
(PAS) staining of tubules and
glomeruli, and Sirius Red
staining. Experimental groups:
WT + vehicle (Veh; 100 μl,
0.1 mol/l citrate buffer, i.p. for
5 days); WT + STZ (45 mg/kg,
0.1 mol/l citrate buffer, i.p. for
5 days); Anxa1−/− + vehicle
(100 μl, 0.1 mol/l citrate buffer,
i.p. for 5 days) and Anxa1−/− +
STZ (45 mg/kg, 0.1 mol/l citrate
buffer, i.p. for 5 days). Black bars,
vehicle; white bars, STZ. Scale
bars, 100 μm. Data analysis was
performed by a one-way ANOVA
followed by a Bonferroni post hoc
test and expressed as mean ±
SEM. n = 6–8 per group.
*p < 0.05, **p < 0.01,
***p < 0.001
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and FAC (Fig. 5a–c) suggesting that daily treatment with
hrANXA1 (from weeks 1–13) protects against the develop-
ment of cardiac dysfunction.
Similarly, when renal function was assessed, diabetic
mice demonstrated significantly elevated ACR, serum
urea and fractional excretion of sodium, while treatment
with hrANXA1 from weeks 1–13 significantly attenuat-
ed these increases (Fig. 5d–f). These findings suggest
that hrANXA1 protects against the development of renal
dysfunction caused by STZ-induced diabetes. Treatment
with hrANXA1 on days 1–5 had no effect on EF, FS,
FAC, ACR, serum urea or fractional excretion of sodi-
um (Fig. 5a–f).
Therapeutic treatment (weeks 8–13) with hrANXA1 halts
the progression of renal and cardiac dysfunction caused
by STZ-induced type 1 diabetes When compared with dia-
betic mice, diabetic mice given therapeutic treatment of
hrANXA1 (weeks 8–13) exhibited no difference in insulin
levels, non-fasted blood glucose and OGTT impairment
(Table 1). When left ventricular function was assessed using
echocardiography, diabetic mice demonstrated a significant
reduction in EF, FS and FAC (Fig. 6a–c) from week 7 to week
13. Interestingly, mice given therapeutic treatment with
hrANXA1 (weeks 8–13) demonstrated no decline in EF, FS
and FAC (Fig. 6a–c) from week 7 to week 13, suggesting that
late treatment with hrANXA1 can halt the progression of car-
diac dysfunction.
Similarly, renal function was assessed at weeks 7 and
13, diabetic mice demonstrated a significant increase in
ACR, serum urea and fractional excretion of sodium (Fig.
6d–f) from week 7 to week 13. Interestingly, mice given
therapeutic treatment with hrANXA1 (weeks 8–13) dem-
onstrated no significant increase in serum urea and frac-
tional excretion of sodium (Fig. 6e, f), suggesting that late
treatment with hrANXA1 may reduce progression of tubu-
lar dysfunction associated with STZ-induced diabetes.
However, ACR did increase but not to the same degree as
Fig. 4 Signalling in the kidney was assessed 13 weeks after STZ induc-
tion of type 1 diabetes mellitus. Densitometric analysis of bands is
expressed relative to sham absorbance of (a) phosphorylated Akt
(pSer473) corrected to total Akt and normalised using the WT + vehicle
band; (b) phosphorylated p38 (pThr180/Tyr182) corrected to total p38 and
normalised using the WT + vehicle band; (c) phosphorylated JNK
(pThr183/Tyr185) corrected to total JNK and normalised using the WT +
vehicle band; and (d) phosphorylated ERK1/2 (pThr202/Tyr204) corrected
to total ERK1/2 and normalised using the WT + vehicle band.
Experimental groups: WT + vehicle (100 μl, 0.1 mol/l citrate buffer,
i.p. for 5 days); WT + STZ (45 mg/kg, 0.1 mol/l citrate buffer, i.p. for
5 days);Anxa1−/− + vehicle (100μl, 0.1mol/l citrate buffer, i.p. for 5 days)
and Anxa1−/− + STZ (45 mg/kg, 0.1 mol/l citrate buffer, i.p. for 5 days).
Representative images from one of three repeated experiments are shown.
Black bars, vehicle; white bars, STZ. In (d): solid bars, ERK1; hatched
bars, ERK2. Data analysed by a one-way ANOVA followed by a
Bonferroni post hoc test and expressed as mean ± SEM. n = 6–8 per
group. *p < 0.05
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in mice treated with vehicle (Fig. 6d), suggesting a small
but significant reduction in proteinuria.
Treatment with hrANXA1 restores normal signalling
events in the heart and kidney after STZ-induced type 1
diabetes Diabetic mice exhibited a significant increase in the
degree of phosphorylation of Thr180/Tyr182 on p38, Thr183/
Tyr185 on JNK and Thr202/Tyr204 on ERK1/2 in both the heart
and kidney (Fig. 7) compared with WTmice. Moreover, treat-
ment with hrANXA1 from weeks 1–13 attenuated the in-
crease in phosphorylation of Thr180/Tyr182 on p38, Thr183/
Tyr185 on JNK and Thr202/Tyr204 on ERK1/2 in both the heart
and kidney (Fig. 7). Similarly, therapeutic treatment with
hrANXA1 (weeks 8–13) attenuated the increase in phosphor-
ylation of Thr183/Tyr185 on JNK and Thr202/Tyr204 on ERK1/2
in both the heart and kidney (Fig. 7d, f), and Thr180/182 on p38
in the heart (Fig. 7a).
Diabetic mice exhibited significantly less phosphorylation
of Ser473 on Akt in the heart and kidney (Fig. 7g, h) compared
with non-diabetic mice. Such data suggest that Akt signalling
is blunted and could be restored when mice were treated with
hrANXA1 from weeks 1–13 in both the heart and kidney,
while therapeutic treatment with hrANXA1 (weeks 8–13) also
restored the phosphorylation of Ser473 of Akt in the heart but
not the kidney.
Discussion
ANXA1 levels are elevated in individuals with type 1 diabe-
tes. The main conceptually novel findings of this study are: (1)
Anxa1−/− mice challenged with STZ developed a more severe
diabetic phenotype and more severe systolic cardiac and renal
dysfunction compared with diabetic WT mice; (2) prophylac-
tic treatment of diabetic mice with hrANXA1 did not prevent
the development of a diabetic phenotype but attenuated the
development of both cardiac and renal dysfunction; and (3)
therapeutic administration of hrANXA1 (after both cardiac
and renal dysfunction had developed) halted the progression
of both cardiac and renal dysfunction seen in diabetic WT
mice. Thus, endogenous ANXA1 prevents the development
of end-organ injury in a murine model of type 1 diabetes and
therapeutic hrANXA1 prevents (prophylactic administration)
or halts (late therapeutic administration) the progression of
systolic cardiac dysfunction and proteinuria caused by diabe-
tes in these animals without altering the underlying diabetic
phenotype.
Type 1 diabetes is characterised by elevated blood glucose
levels, which drives low-grade chronic inflammation and thus
contribute to tissue/organ damage. Healthy donors have low
levels of ANXA1 in plasma [26]. Here we report that ANXA1
is elevated in individuals with type 1 diabetes with and with-
out nephropathy (Fig. 1a). Additionally, we show that diabetic
individuals have elevated systemic inflammation levels,
which are further elevated by nephropathy. Elevated plasma
CRP is strongly associated with adverse outcomes in myocar-
dial infarction, stroke and coronary heart disease, which are
common causes of death in people with type 1 diabetes. We
hypothesise that the elevation in circulating ANXA1 is a com-
pensatory mechanism to protect tissues from the deleterious
effects of hyperglycaemia, independent of the presence of
diabetic nephropathy and not as a consequence of a rise in
systemic inflammation (ESM Fig. 1b). ANXA1 is found in
many tissues, including the heart and kidney, but is also highly
Fig. 5 Measurement of cardiac
and renal function after
prophylactic administration of
hrANXA1 (weeks 1–13): (a) EF,
(b) FS (c) FAC, (d) urine ACR,
(e) serum urea and (f) fractional
excretion of sodium.
Experimental groups: sham (no
STZ; black bars); STZ + vehicle
(white bars); STZ + hrANXA1
weeks 1–13 (1 μg hrANXA1, i.p.
daily weeks 1–13; light grey
bars); STZ + hrANXA1 days 1–5
(1 μg hrANXA1, i.p. for 5 days;
dark grey bars). Data analysed by
a one-way ANOVA followed by a
Bonferroni post hoc test and
expressed as mean ± SEM. n = 6–
8 per group. *p < 0.05
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expressed in macrophages and other immune cells [26]. Here
we report that ANXA1 levels were lower in both the heart and
kidney, suggesting that hyperglycaemia causes ANXA1 to be
released from tissue stores. ANXA1 secretion is needed so it
can signal to the FRP2 in both an autocrine and paracrine
manner to activate tissue/organ protective pathways [12, 27].
We therefore wanted to understand the role of endogenous
ANXA1 in the development of type 1 diabetes and in tissue/
organ protection in the mouse. Mice challenged with STZ de-
veloped a diabetic phenotype with elevated non-fasted blood
glucose levels and impairment in OGTT secondary to a very
large (>75%) reduction in serum insulin levels. In individuals
with type 1 diabetes, beta cell mass is irreversibly reduced by
70–80% at the time of diagnosis [28]; similar loss of beta cells is
recorded in mice administered STZ [29]. We report here that the
diabetic phenotype (OGTT) caused by STZ is more severe in
diabetic Anxa1−/− mice, although the serum insulin levels are
reduced to a similar degree (Table 1). This finding suggests that
endogenous ANXA1 limits the development of hyperglycaemia
in an insulin-independent manner.
Even individuals who undergo rigorous insulin manage-
ment develop microvascular complications over time [30].
Here we report that diabetic Anxa1−/− mice have more severe
cardiac and renal dysfunction compared with diabetic WT
mice, suggesting that endogenous ANXA1 limits the devel-
opment of end-organ injury/dysfunction in mice with diabetes
(Figs 2, 3). As hypertrophy is an important contributor in
diabetes-associated cardiac and renal dysfunction we evaluat-
ed both intra-ventricular septum diameter [31] and glomerular
size; and report that both are significantly increased in diabetic
mice (Figs 2, 3). Notably, both glomerular hypertrophy and
interstitial fibrosis were further significantly augmented in di-
abetic Anxa1−/−mice when compared with diabetic WT mice.
Cardiac hypertrophy is a common response to external
stressors, including hyperglycaemia and oxidative stress
[32]; this compensatory process evolves into a decompensated
state with profound changes in contractile dysfunction and
extracellular remodelling [33]. Similarly, renal hypertrophy
is also a compensatory mechanism [34]; in the case of type
1 diabetes, excessive renal hyperfiltration due to activation of
the renin–angiotensin pathways [35] puts stress on glomeruli
and proximal tubules [35], manifesting in functional decline.
Having found that endogenous ANXA1 limits the develop-
ment of microvascular complications associated with diabetes,
we wanted to investigate whether pharmacological interven-
tion with hrANXA1 can attenuate the development of diabetic
Fig. 6 Measurement of cardiac and renal function after therapeutic ad-
ministration of hrANXA1 (weeks 8–13). Measurements were taken be-
fore treatment (at week 7) and after treatment (at week 13): (a) EF, (b) FS
and (c) FAC, and (d) urine ACR, (e) serum urea and (f) fractional excre-
tion of sodium. Experimental groups: sham (no STZ); STZ + vehicle;
STZ + hrANXA1 weeks 8–13 (1 μg hrANXA1, i.p. daily weeks 1–13).
Black bars, 7 weeks; white bars, 13 weeks. Data analysed by a one-way
ANOVA followed by a Bonferroni post hoc test and expressed as mean ±
SEM. n = 6–8 per group. *p < 0.05
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Fig. 7 Signalling in the heart (a, c, e, g) and kidney (b, d, f, h) was
assessed 13 weeks after STZ induction of type 1 diabetes mellitus.
Densitometric analysis of bands is expressed as relative to sham absor-
bance of (a, b) p-p38 (p-Thr180/Tyr182) corrected to total p38 and normal-
ised using theWT+ vehicle band; (c, d) p-JNK (p-Thr183/Tyr185) corrected
to total JNK and normalised using the sham band; (e, f) p-ERK1/2 (p-
Thr202/-Tyr204) corrected to total ERK1/2 and normalised using the sham
band; and (g, h) p-Akt (p-Ser473) corrected to total Akt and normalised
using sham band. Experimental groups: sham (no STZ; black bars); STZ +
vehicle (white bars); STZ + hrANXA1 weeks 1–13 (1 μg hrANXA1, i.p.
daily weeks 1–13; light grey bars); STZ + hrANXA1 days 1–5 (1 μg
hrANXA1, i.p. for 5 days; dark grey bars) and STZ + hrANXA1 weeks
8–13 (1 μg hrANXA1, i.p. weeks 8–13, grey hatched bars). In (e, f): solid
bars, ERK1; hatched bars, ERK2; for the STZ + hrANXA1 weeks 8–13
condition, ERK1, horizontal hatching, ERK2, diagonal hatching.
Representative images from one of three repeated experiments are shown.
Data analysed by a one-way ANOVA followed by a Bonferroni post hoc
test and expressed as mean ± SEM. n = 6–8 per group. *p < 0.05
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cardiomyopathy and nephropathy. Previously, both full-length
AXNA1 and the Ac2-26 peptide (the N-terminal functional
fragment of ANXA1) have been used in vivo and both elicit
biological function [17–19]). In this study, we chose to use full-
length hrANXA1, as the dose of full-length ANXA1 needed to
induce biological function is up to 20 times less than that of the
Ac2-26 peptide [36] and 14 times less than that needed to
induce changes in gene expression in terms of molarity [37].
Treatment of mice challenged with STZ with hrANXA1
(weeks 1–13) did not alter the diabetic phenotype (reduced
insulin levels, elevated blood glucose and impaired OGTT),
but attenuated the cardiac dysfunction and the proteinuria
caused by diabetes, suggesting that hrANXA1 reduces the
cardiac and renal injury caused by hyperglycaemia and exces-
sive oxidative stress (organ protection rather than reduction of
diabetes). Most notably, we also report that a late therapeutic
intervention (weeks 8–13), when a diabetic phenotype and a
moderate degree of cardiac and renal dysfunction had already
occurred, halted the further decline in both cardiac and renal
function seen in diabetic WT mice. It should be noted that
administration of ANXA1 during the administration of STZ
(days 1–5) was also not sufficient to reduce the diabetic phe-
notype or give long-term protection to organs.
What are the mechanisms by which ANXA1 elicits protec-
tion against cardiac and renal dysfunction associated with di-
abetes? We show here for the first time that the development
of type 1 diabetes (caused by STZ) in mice is associated with
(1) a reduction in endogenous ANXA1 levels in both the heart
and the kidney (increased secretion) and (2) a decline in car-
diac and renal dysfunction. Thus, we speculated that endoge-
nous ANXA1 protects both the heart and the kidney (and
hence reduces organ injury/dysfunction) by acting on pro-
survival and anti-inflammatory pathways.
Hyperglycaemia leads to activation (phosphorylation) of
mitogen-activated protein kinases (MAPKs) p38, JNK and
ERK1/2, hypertrophy and fibrosis in the heart [32–38] and
kidney [39, 40]. While little evidence is available to suggest
strong tissue specific activation of proinflammatory pathways
in STZ-induced diabetes, pharmacological inhibition or genet-
ic deletion of any of these threeMAPKs reduces microvascular
complications (diabetic nephropathy, cardiomyopathy and ret-
inopathy) caused by type 1 diabetes in rodents [41, 42]. Indeed
we found no activation of NF-κB or the inflammasome in our
model of STZ-induced diabetes (ESM Fig. 4). However, we
observed a significant increase in activated (phosphorylated)
p38, JNK and ERK1/2 in diabetic WT mice. Interestingly,
Anxa1−/− mice, even in the absence of diabetes (no STZ chal-
lenge), had constitutive activation (phosphorylation) of p38,
JNK and ERK1/2 in the heart and kidney. The degree of acti-
vation of p38, JNK and ERK1/2 was further exacerbated when
Anxa1−/− mice were challenged with STZ. As diabetic
Anxa1−/− mice also had excessive renal hypertrophy and
fibrosis, we speculate that the excessive activation of these
known proinflammatory and profibrotic signalling pathways
are key drivers of the excessive pathology seen in Anxa1−/−
mice. This hypothesis is supported by the following two
findings: (1) treatment of diabetic WT mice with hrANXA1
attenuated the activation of p38, JNK and ERK1/2 and the
cardiac and renal dysfunction caused by diabetes; and (2) even
when hrANXA1 was given therapeutically (weeks 8–13) this
resulted in attenuation of the activation of p38, JNK and
ERK1/2 as well as the organ dysfunction caused by diabetes.
In addition, we also investigated the effect of diabetes with
or without hrANXA1 treatment on the degree of activation of
Akt survival pathways, which is in part regulated by IRS-1
[43]. Diabetic mice demonstrated a significant decrease in the
phosphorylation of Ser473 on Akt (indicating a reduction in
activity of the kinase) in the heart and kidney. One effect of
this inhibition is that organs are less resistant to stressor stimuli
and subsequent organ injury. In contrast, treatment with
hrANXA1 attenuated the decline in Akt activation caused by
diabetes. Akt is a member of the phosphoinositide-3 kinase
(PI3K) signal transduction pathway. Insulin signalling
through IRS-1 regulates PI3K activity and PI3K can activate
Akt (phosphorylation on Ser473). Activated Akt controls in-
flammatory and pro-survival responses [44]. Most notably,
activation of the Akt survival pathway reduces organ injury
in many conditions associated with inflammation including
sepsis-induced organ dysfunction [20, 45], haemorrhagic
shock-induced organ dysfunction [25, 46], myocardial infarc-
tion [47] and diabetes [48]. Specifically, in cardiac and renal
ischaemia/reperfusion injury treatment with the Ac2-16 pep-
tide tissue necrosis was reduced by activation of Akt [49, 50].
In conclusion, we report for the first time that ANXA1
levels are elevated in the plasma of individuals with type 1
diabetes. We have also clearly demonstrated that endogenous
ANXA1 plays a key role in protecting the heart and kidney
from functional decline in an animal model of type 1 diabetes.
Specifically, we have shown that key mediators of the MAPK
pathway (p38, JNK and ERK1/2) are constitutively activated
in Anxa1−/− mice. Administration of hrANXA1 attenuated
both cardiac and renal dysfunction caused by STZ induction
of diabetes. While late treatment can halt both cardiac and
renal dysfunction. We propose that attenuation of MAPK
pathway signalling and restoration/activation of Akt survival
pathways mediates these effects. Thus, we propose that treat-
ment with hrANXA1 may represent a novel new intervention
of microvascular complications caused by type 1 diabetes.
Data availability All data generated or analysed during this study are
included in this published article (and its supplementary information file).
Funding We would like to thank the following funding bodies: the
British Heart Foundation (Award number: FS/13/58/30648) to GP; the
Ministry of Education, Brazil (Grant number: 7326/2014-09) to RAL;
University of Turin (Ricerca Locale Linea B 2015 and Linea A 2016)
Diabetologia (2018) 61:482–495 493
to MC; the William Harvey Research Foundation to CT; Bart’s and The
London Charity Centre of Diabetic Kidney Disease (programme grant:
577/2348) to MY and CT; and FISM Fondazione Italiana Sclerosi
Multipla–Cod. 2014/R/21 to ES. We acknowledge support from the
National Institute for Health and Research, Biomedical Research Centre
award to Guy’s and St Thomas Foundation Trust in partnership with
King’s College London.
Duality of interest No conflict of interest declared.
Contribution statement All authors made substantial contributions to
conception and design, acquisition of data and interpretation of data; GP,
LG, MC, CT and ES drafted the manuscript and provided important
intellectual content; all authors reviewed and approved the manuscript.
GP, CT and ES are the guarantors of this work.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. AtkinsonMA, Eisenbarth GS,Michels AW (2014) Type 1 diabetes.
Lancet 383:69–82
2. Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C
(2016) Diabetic nephropathy in type 1 diabetes: a review of early
natural history, pathogenesis, and diagnosis. Diabetes Metab Res
Rev 33:e2841
3. Bugger H, Abel ED (2014) Molecular mechanisms of diabetic car-
diomyopathy. Diabetologia 57:660–671
4. The National Institute for Health and Care Excellence (2015) Type
1 diabetes in adults: diagnosis and management (Nice guideline
NG17). Available from www.nice.org.uk/guidance/ng17.
Accessed 16 Jan 2017
5. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, del
Cañizo-Gómez FJ (2014) Type 2 diabetes and cardiovascular dis-
ease: have all risk factors the same strength? World J Diabetes 5:
444–470
6. Bhattacharjee N, Barma S, Konwar N et al (2016) Mechanistic
insight of diabetic nephropathy and its pharmacotherapeutic targets:
an update. Eur J Pharmacol 791:8–24
7. Niemann M, Herrmann S, Ertl G, Weidemann F (2013)
Echocardiography in diabetic cardiomyopathy. Herz 38:42–47
8. Downs CA, Faulkner MS (2015) Toxic stress, inflammation and
symptomatology of chronic complications in diabetes. World J
Diabetes 6:554–565
9. Shi Y, Vanhoutte PM (2017) Macro- and microvascular endothelial
dysfunction in diabetes. J Diabetes 9:434–449
10. Flower RJ, Blackwell GJ (1979) Anti-inflammatory steroids induce
biosynthesis of a phospholipase A2 inhibitor which prevents pros-
taglandin generation. Nature 278:456–469
11. Rosengarth A, Gerke V, Luecke H (2001) X-ray structure of full-
length annexin 1 and implications for membrane aggregation. J Mol
Biol 306:489–498
12. Perretti M, D’Acquisto F (2009) Annexin A1 and glucocorticoids
as effectors of the resolution of inflammation. Nat Rev Immunol 9:
62–70
13. Shen D, Nooraie F, Elshimali Y et al (2006) Decreased expression
of annexin A1 is correlated with breast cancer development and
progression as determined by a tissue microarray analysis. Hum
Pathol 37:1583–1591
14. Cristante E, McArthur S, Mauro C et al (2013) Identification of an
essential endogenous regulator of blood-brain barrier integrity, and
its pathological and therapeutic implications. Proc Natl Acad Sci U
S A 110:832–841
15. Bensalem N, Ventura AP, Vallée B et al (2005) Down-regulation of
the anti-inflammatory protein annexin A1 in cystic fibrosis knock-
out mice and patients. Mol Cell Proteomics 4:1591–1601
16. Kosicka A, Cunliffe AD, Mackenzie R et al (2013) Attenuation of
plasma annexin A1 in human obesity. FASEB J 27:368–378
17. Renshaw D,Montero-Melendez T, Dalli J et al (2010) Downstream
gene activation of the receptor ALX by the agonist annexin A1.
PLoS One 5:e12771
18. Kusters DHM, Chatrou ML, Willems BAG et al (2015)
Pharmacological treatment with annexin A1 reduces atherosclerot-
ic plaque burden in LDLR-/- mice on western type diet. PLoS One
10:e0130484
19. Locatelli I, Sutti S, Jindal A et al (2014) Endogenous annexin A1 is
a novel protective determinant in nonalcoholic steatohepatitis in
mice. Hepatology 60:531–544
20. Chen J, Kieswich JE, Chiazza F et al (2017) IκB kinase inhibitor
attenuates sepsis-induced cardiac dysfunction in CKD. J Am Soc
Nephrol 28:94–105
21. Smith SF, Goulding NJ, Godolphin JL et al (1990) An assay for the
assessment of lipocortin 1 levels in human lung lavage fluid. J
Immunol Methods 131:119–125
22. Yang YH, Morand EF, Getting SJ et al (2004) Modulation of in-
flammation and response to dexamethasone by Annexin 1 in
antigen-induced arthritis. Arthritis Rheum 50:976–984
23. McArthur S, Cristante E, Paterno M et al (2010) Annexin A1: a
central player in the anti-inflammatory and neuroprotective role of
microglia. J Immunol 185:6317–6328
24. Johnson FL, Patel NSA, Purvis GSD et al (2017) Inhibition of IκB
kinase at 24 hours after acute kidney injury improves recovery of
renal function and attenuates fibrosis. J AmHeart Assoc 6:e005092
25. Yamada N, Martin LB, Zechendorf E et al (2017) Novel synthetic,
host-defense peptide protects against organ injury/dysfunction in a
rat model of severe hemorrhagic shock. Ann Surg. https://doi.org/
10.1097/SLA.0000000000002186
26. Gavins FNE, Hickey MJ (2012) Annexin A1 and the regulation of
innate and adaptive immunity. Front Immunol 3(354):1–11
27. Dalli J, Consalvo AP, Ray V et al (2013) Proresolving and tissue-
protective actions of annexin A1-based cleavage-resistant peptides
are mediated by formyl peptide receptor 2/lipoxin A4 receptor. J
Immunol 190:6478–6487
28. Akirav E, Kushner JA, Herold KC (2008) Beta-cell mass and type 1
diabetes: going, going, gone? Diabetes 57:2883–2888
29. Szkudelski T (2001) The mechanism of alloxan and streptozotocin
action in B cells of the rat pancreas. Physiol Res 50:536–546
30. AtkinsonMA (2012) The pathogenesis and natural history of type 1
diabetes. Cold Spring Harb Perspect Med 2:a007641
31. Way KJ, Isshiki K, Suzuma K et al (2002) Expression of connective
tissue growth factor is increased in injured myocardium associated
with protein kinase C β2 activation and diabetes. Diabetes 51:
2709–2718
32. Diwan A, Dorn GW (2007) Decompensation of cardiac hypertro-
phy: cellular mechanisms and novel therapeutic targets. Physiology
22:56–64
33. Festa A, Haffner SM (2005) Inflammation and cardiovascular dis-
ease in patients with diabetes: lessons from the Diabetes Control
and Complications Trial. Circulation 111:2414–2425
34. Reidy K, Kang HM, Hostetter T, Susztak K (2014) Molecular
mechanisms of diabetic kidney disease. J Clin Invest 124:2333–
2340
494 Diabetologia (2018) 61:482–495
35. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW (2012)
Glomerular hyperfiltration: definitions, mechanisms and clinical
implications. Nat Rev Nephrol 8:293–300
36. Solito E, Romero IA, Marullo S et al (2000) Annexin 1 binds to
U937 monocytic cells and inhibits their adhesion to microvascular
endothelium: involvement of the 4 1 integrin. J Immunol 165:
1573–1581
37. Rodrigues-Lisoni FC,Mehemet DK, Peitl P et al (2006) In vitro and
in vivo studies on CCR10 regulation by annexin A1. FEBS Lett
580:1431–1438
38. Naito Z, Takashi E, Xu G et al (2003) Different influences of hy-
perglycemic duration on phosphorylated extracellular signal-
regulated kinase 1/2 in rat heart. Exp Mol Pathol 74:23–32
39. Komers R, Lindsley JN, Oyama TT et al (2007) Renal p38 MAP
kinase activity in experimental diabetes. Lab Investig 87:548–558
40. Cheng X, GaoW, Dang Yet al (2013) Both ERK/MAPK and TGF-
Beta/Smad signaling pathways play a role in the kidney fibrosis of
diabetic mice accelerated by blood glucose fluctuation. J Diabetes
Res. https://doi.org/10.1155/2013/463740
41. Du Y, Tang J, Li G et al (2010) Effects of p38 MAPK inhibition on
early stages of diabetic retinopathy and sensory nerve function.
Invest Ophthalmol Vis Sci 51:2158–2164
42. Singh GB, Raut SK, Khanna S et al (2017) MicroRNA-200c mod-
ulates DUSP-1 expression in diabetes-induced cardiac hypertrophy.
Mol Cell Biochem 424:1–11
43. Guo S (2014) Insulin signaling, resistance, and the metabolic syn-
drome: insights from mouse models into disease mechanisms. J
Endocrinol 220:T1–T23
44. Cantley LC (2002) The phosphoinositide 3-kinase pathway.
Science 296:1655–1657
45. Khan AI, Coldewey SM, Patel NSA et al (2013) Erythropoietin
attenuates cardiac dysfunction in experimental sepsis in mice via
activation of the β-common receptor. Dis Model Mech 6:1021–
1030
46. Sordi R, Nandra KK, Chiazza F et al (2017) Artesunate protects
against the organ injury and dysfunction induced by severe hemor-
rhage and resuscitation. Ann Surg 265:408–417
47. Cai Z, Semenza GL (2004) Phosphatidylinositol-3-kinase signal-
ling is required for erythropoietin-mediated acute protection against
myocardial ischemia/reperfusion injury. Circulation 109:2050–
2063
48. Chiazza F, Couturier-Maillard A, Benetti E et al (2015) Targeting
the NLRP3 inflammasome to reduce diet-induced metabolic abnor-
malities in mice. Mol Med 21:1025–1037
49. Qin C, Buxton KD, Pepe S et al (2013) Reperfusion-induced myo-
cardial dysfunction is prevented by endogenous annexin-A1 and its
N-terminal-derived peptide Ac-ANX-A1 2-26. Br J Pharmacol 168:
238–252
50. Facio FN, Sena AA, Araújo LP et al (2011) Annexin 1 mimetic
peptide protects against renal ischemia/reperfusion injury in rats. J
Mol Med 89:51–63
Diabetologia (2018) 61:482–495 495
